Healthcare can be complicated.
Your cardiology news shouldn’t be.

Join thousands of cardiology leaders today.

Pharmaceuticals November 13, 2023

Lilly’s Zepbound (aka tirzepatide) Lands FDA Approval for Weight Loss November 13, 2023

The US obesity management arena gained a major new competitor last week with the FDA approval of Eli Lilly’s Zepbound, giving obese and overweight patients in the US a second (on-label) option beyond Novo Nordisk’s Wegovy.

Surgeries & Interventions November 9, 2023

Recor Medical’s Paradise Renal Denervation System Lands FDA Approval November 9, 2023

The renal denervation race hit a major new milestone this week after Recor Medical’s Paradise system became the first to land FDA approval for hypertension.

Population Health November 6, 2023

America’s Cholesterol Awareness Problem November 6, 2023

The prevalence of US adults with high LDL cholesterol levels, and the prevalence of adults who are unaware of their high LDL-C are both declining. However, these improvements aren't happening nearly fast enough - especially given our expanding cholesterol treatment options.

Pharmaceuticals November 2, 2023

Chinese Medicine Tongxinluo Improves STEMI Outcomes, Sparks Debates November 2, 2023

Could the next major heart attack treatment come from a traditional Chinese medicine? A new JAMA study suggests that might be more realistic than many of us think, after showing that the Chinese medicine Tongxinluo significantly improves outcomes among patients with acute ST-segment elevation myocardial infarction (STEMI).

Surgeries & Interventions October 30, 2023

Promising Drug-Coated Balloon Results for In-Stent Restenosis October 30, 2023

The United States has been way behind other nations in using drug-coated balloons to treat coronary in-stent restenosis, but that might change soon thanks to the results from the AGENT IDE Trial.

Artificial Intelligence October 26, 2023

Healthcare AI Clearances Boom, While Cardiology AI Stalls October 26, 2023

The FDA’s annual Healthcare AI Report had medtech social media buzzing this week, showing that an impressive 692 AI-enabled devices have landed FDA clearance as of July 2023, while revealing an apparent slowdown in cardiovascular AI approvals.

Pharmaceuticals October 23, 2023

Pemvidutide’s Weight Loss and CVD Evidence October 23, 2023

Interim Phase 2 results from the MOMENTUM trial show that Altimmune’s pemvidutide drove significant weight loss and improved key cardiovascular metrics.

Pharmaceuticals October 19, 2023

Novo Nordisk Expands CV Pipeline with Ocedurenone Acquisition October 19, 2023

Novo Nordisk took advantage of its semaglutide windfall, expanding its cardiovascular drug pipeline by acquiring ocedurenone from KBP Biosciences for $1.3 billion.

Cardiology October 13, 2023

GE and Mediport’s One-Stop Cardiology Clinic October 13, 2023

With a direct target on streamlining the cardiovascular care pathway, GE HealthCare and Belgian healthcare organization Mediport announced the launch of the first One-Stop Clinic for Cardiology.

Pharmaceuticals October 12, 2023

Semaglutide Adds to Cardiovascular Resume October 12, 2023

Semaglutide continued to add to its cardiovascular resume, with two new studies highlighting its ability to improve heart failure symptoms and cardiorenal outcomes.

Value-Based Care October 9, 2023

CVAUSA and InnovaCare’s Value-Based Alliance October 9, 2023

A new Cardiovascular Associates of America and InnovaCare Health is aiming to create a new model for cardiology + primary care VBC delivery.

Cardiology October 5, 2023

MedAxiom on the State of Cardiovascular Providers October 5, 2023

MedAxiom just released its 11th annual Compensation and Production Report, revealing general stability in 2022 after years of significant change.

Surgeries & Interventions October 2, 2023

Adena Health Pauses Cardiac Surgeries Amid Mounting Controversies October 2, 2023

Ohio’s Adena Health System has temporarily stopped performing heart surgeries, after months of growing scrutiny and some troubling deaths.

Population Health September 28, 2023

The CDC’s Heavy Obesity Update September 28, 2023

Obesity is easily among the leading cardiovascular disease risk factors, and its overall impact on public cardiovascular health could be rising faster than many of us might imagine. In just 10 years, the U.S. went from having zero states with an obesity prevalence above 35% to a whopping 22 states in 2022.

Cardiology September 25, 2023

Cardiovascular Societies Seek A Board of Their Own September 25, 2023

After months of growing cardiologist backlash against the ABIM’s Maintenance of Certification program, four leading cardiovascular societies collectively announced plans to create a new cardiology board to replace it.

Pharmaceuticals September 21, 2023

Abelacimab Significantly Reduces Bleeding September 21, 2023

Anthos Therapeutics celebrated its Phase II results showing that its Factor XI inhibitor abelacimab significantly reduced bleeding among AFib patients compared to rivaroxaban.

Cardiology September 18, 2023

Cardiology in 2073 September 18, 2023

Most of cardiology today was unknown or in its very early stages fifty years ago, and this forecast suggests that “cardiology will change as much in the next 50 years.”

Pharmaceuticals September 14, 2023

Lorundrostat’s Safe and Effective Blood Pressure Control September 14, 2023

An aldosterone inhibitor called lorundrostat took a step towards becoming the first new antihypertensive agent class in nearly 15 years, after safely and effectively treating patients with uncontrolled blood pressure in a Phase II trial.

Pharmaceuticals September 11, 2023

Zilebesiran Phase 2 Results Show Long-Lasting Blood Pressure Impact September 11, 2023

Zilebesiran’s path towards becoming the first long-lasting antihypertensive medication gained more momentum, with new topline Phase 2 results demonstrating that a single injection significantly reduces systolic blood pressure through six months.

Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like..

Select All

You're signed up!

It's great to have you as a reader. Check your inbox for a welcome email.

-- The Cardiac Wire Team

You're all set!